U.S. Software Stock News

Crinetics Pharmaceuticals recently completed a US$350.14 million follow-on common stock offering after reporting over US$5 million in preliminary fourth-quarter 2025 PALSONIFY revenue and positive Phase 2 atumelnant data in classic congenital adrenal hyperplasia. Together, these updates highlight early commercial traction for PALSONIFY and clinical progress for atumelnant, while the equity raise may bolster Crinetics’ ability to fund further development and commercialization. We’ll now...

Delta Air Lines (DAL) has just wrapped up FY 2025 with Q4 revenue of US$16.0b and basic EPS of US$1.88, alongside net income excluding extra items of US$1,219m. Over the past year, revenue on a trailing twelve month basis moved from US$61.6b with EPS of US$5.39 to US$63.4b with EPS of US$7.72, while trailing net income excluding extra items rose from US$3,457m to US$5,005m. For investors, the current earnings outline a picture of firmer margins and profitability that now need to be weighed...

Caris Life Sciences (CAI) recently announced a partnership with Everlywell to launch Caris Detect, a multi cancer early detection blood test that uses whole genome sequencing and AI analysis. See our latest analysis for Caris Life Sciences. Despite the Everlywell partnership and recent preliminary 2025 numbers that highlighted revenue growth and higher case volumes, momentum in Caris Life Sciences' share price has been soft. The 90 day share price return is 15.28% and the year to date share...

Autolus Therapeutics recently reported preliminary unaudited 2025 net product revenue of about US$75 million and issued 2026 guidance of US$120 million to US$135 million, alongside progressing obe-cel into Phase 2 trials for lupus nephritis and other indications. The company also secured UK and EU approvals for AUCATZYL®, pairing early commercial traction with expanding clinical data in both pediatric oncology and autoimmune disease. Next, we’ll examine how this combination of higher revenue...

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Highwoods Properties, Inc. recently acquired the Bloc83 office complex in Raleigh’s CBD and The Terraces in Dallas’ Preston Center through joint ventures, planning to fund these deals largely via non-core asset sales within a leverage-neutral capital rotation by mid-2026. The company expects these acquisitions to immediately add to cash flows while upgrading its office portfolio toward higher-quality assets with stronger long-run income potential. We’ll now examine how funding these...

Alliant Energy’s Board of Directors recently declared a quarterly cash dividend of US$0.5350 per share, payable on February 17, 2026, and previously announced the appointment of former PJM Interconnection President and CEO Manu Asthana as an independent director effective February 23, 2026. Asthana’s deep experience in grid operations, power markets and risk management, combined with the higher cash payout, may influence how investors view Alliant Energy’s governance, capital priorities and...

Analyst sentiment shift puts DXP Enterprises (DXPE) in focus Fresh analyst commentary on DXP Enterprises (DXPE), including upward revisions to earnings estimates and a consensus in the strong buy to buy range, has put the industrial distributor back on many investors’ watchlists. See our latest analysis for DXP Enterprises. DXP’s share price has moved up to US$115.48, with a 7 day share price return of 5.27% and a year to date share price return of 7.20%. Its 1 year and 5 year total...

As the U.S. market navigates a landscape marked by fluctuating indices and inflation data that aligns with expectations, investors are keenly assessing the implications for high-growth sectors like technology. In this environment, identifying promising tech stocks involves evaluating companies that demonstrate resilience amidst economic shifts and possess innovative capabilities to capitalize on emerging opportunities.

As the U.S. stock market navigates through a landscape of record highs and inflationary pressures, investors are keenly assessing the implications of recent consumer price index data and corporate earnings reports. In this environment, identifying undervalued stocks requires a careful analysis of fundamentals and market sentiment, offering potential opportunities for those looking to capitalize on discrepancies between current valuations and intrinsic worth.

As the U.S. stock market navigates a period of cautious optimism following recent inflation data and mixed corporate earnings, investors are increasingly focused on identifying resilient growth opportunities. In this context, companies with high insider ownership often stand out as promising candidates, suggesting that those who know the business best have confidence in its future prospects.

As the U.S. stock market experiences a pullback with investors assessing CPI inflation data and major bank earnings, attention turns to alternative investment opportunities like penny stocks. Often considered an outdated term, penny stocks still hold relevance as they represent smaller or newer companies that can offer growth potential at lower price points. When these companies are backed by strong financial fundamentals, they present intriguing options for investors seeking hidden value in...

As the U.S. market navigates a landscape marked by recent inflation data and fluctuating key indices, investors are closely monitoring the performance of small-cap stocks within the S&P 600. With economic indicators showing resilience amid cautious optimism, identifying promising opportunities in lesser-known stocks can be crucial for those seeking to capitalize on potential growth. In this environment, a good stock often exhibits strong fundamentals and adaptability to changing economic...

Despite an already strong run, Planet Labs PBC ( NYSE:PL ) shares have been powering on, with a gain of 39% in the last...

In recent days, Wells Fargo and RBC Capital have each begun or renewed coverage of Phreesia, assigning favorable ratings that highlight its role as a healthcare technology provider with a SaaS-based patient intake platform. This wave of positive analyst attention points to growing institutional focus on how Phreesia’s software, used across thousands of physicians, could influence its growth profile and profitability efforts. Next, we’ll examine how this increase in supportive analyst...

Merit Medical Systems recently issued fourth-quarter 2025 earnings guidance, projecting revenue between US$389,000,000 and US$395,000,000 year-over-year, and confirmed a Board leadership change with F. Ann Millner appointed Chair following the resignation of longtime director and former Chair Fred P. Lampropoulos. This combination of updated revenue expectations and a shift in Board leadership brings fresh attention to how Merit balances growth ambitions with governance continuity. Next, we...

UWM Holdings (UWMC) is back in focus after President Donald Trump announced a US$200b federal program to buy mortgage backed securities. The move is aimed at influencing mortgage rates outside the Federal Reserve’s actions. See our latest analysis for UWM Holdings. The news-driven jump in UWM’s share price sits against mixed recent performance, with a 20% 7 day share price return, a 21.09% year to date share price return, and a 68.11% 3 year total shareholder return. This suggests momentum...

Penske Automotive Group, Inc.'s ( NYSE:PAG ) price-to-earnings (or "P/E") ratio of 11.5x might make it look like a buy...

With no single headline event driving attention to McGraw Hill (MH) today, recent trading performance is doing the talking, including a past 3 months return of about 26% against a softer month and year to date. See our latest analysis for McGraw Hill. Short term, momentum has cooled with a 7 day share price return of 5.0% and a 30 day share price return of 7.7%. However, the 90 day share price return of 25.6% still points to building interest around McGraw Hill at a share price of $15.83. If...

Recently, Andersons has increased its earnings before interest and tax while keeping capital employed broadly unchanged, lifting its return on capital employed to 5.4% from prior losses. This shift suggests Andersons is extracting more profit from its existing asset base, raising questions about how it will reinvest to sustain these improved returns. We’ll now explore how Andersons’ improved return on capital employed may influence its existing investment narrative built around renewables...

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

Spyre Therapeutics (SYRE) is back on investor radar after management outlined six planned proof of concept readouts for 2026 and reported faster enrollment in its SKYLINE ulcerative colitis trial, alongside appointing experienced commercial leader Kate Tansey Chevlen as CCO. See our latest analysis for Spyre Therapeutics. The share price has reacted quickly to the clinical and leadership updates, with a 1-day share price return of 7.15% and a 90-day share price return of 47.81%. The 1-year...

Alamo Group Inc. recently announced that its Board of Directors raised the quarterly dividend to US$0.34 per share, an increase of US$0.04, with the January payout made on January 29, 2026 to shareholders of record as of January 16, 2026. This higher dividend underscores management’s emphasis on returning cash to shareholders and may be viewed as an indication of financial resilience. We’ll now examine how this higher quarterly dividend and cash-return focus feeds into Alamo Group’s existing...

Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...